To: The Shareholders of Cavit Sciences, Inc.

From: Margaret ("Maggie") Smyth, Interim CEO

Effective November 14, 2008, I have been elected as Interim CEO of Cavit inorder to move our Company forward.

Effective November 14, 2008, the corporate headquarters and relatedfacilities of Cavit are located in Paterson, NJ.

Once I have received and reviewed all of Cavit's corporate records andinformation, I will address all concerns and determine the best course ofaction for the Company and its shareholders. The Board of Directors and Iwill review and determine what needs to be done to become a financiallyviable Company.

I plan to answer your questions and concerns with a press release to bedistributed within the next 30 days.

To get things started, I will not take a salary until the Board ofDirectors deems the company financially fit.

In addition, there will be no rent charged to the Company for its corporateoffices, warehousing, distribution and fulfillment center until the Boardof Directors deems the company financially fit.

The above changes are effective immediately.

I truly believe with hard work and the help of others we can make thisCompany a profitable endeavor for all shareholders.

Cavit Sciences, Inc. ("Cavit") is a biotechnology company engaged indeveloping treatments and prevention for cancer, viral infections andrelated diseases. Additional information regarding our drug development,supplement line and Company information is available on the Company'swebsite at: www.cavitsciences.com.

Statements contained herein that are not historical fact may beforward-looking statements within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Act of1934, that are subject to a variety of risks and uncertainties. There area number of important factors that could cause actual results to differmaterially from those projected or suggested in any forward-lookingstatements made by Cavit. These factors include, but are not limited to:(i) the ability of Cavit to successfully raise financing, (ii) the abilityof Cavit to finalize its manufacturing and distribution facilities, and(iii) the ability of Cavit to successfully commercialize its products incertain markets. Additional factors that would cause actual results todiffer materially from those projected or suggested in any forward-lookingstatements are contained in Cavit's filings with the Securities andExchange Commission, including those factors discussed under the caption"Risk Factors" for Cavit on Form 10-K filed on April 18, 2008 and itssubsequently filed Forms 10-Q.

Contact:Maggie SmythInterim CEO(973) 278-7327Cavit Sciences, Inc.www.cavitsciences.com